TCGA-BB-A5HZ-01A-21R-A28V-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.620
- MYC_TARGETS_V1+0.370
- OXIDATIVE_PHOSPHORYLATION+0.370
- UNFOLDED_PROTEIN_RESPONSE+0.300
- FATTY_ACID_METABOLISM+0.140
- ADIPOGENESIS+0.120
- MTORC1_SIGNALING+0.120
- P53_PATHWAY+0.100
- CHOLESTEROL_HOMEOSTASIS+0.080
- ESTROGEN_RESPONSE_LATE+0.040
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.370
- E2F_TARGETS-0.330
- COMPLEMENT-0.310
- APICAL_SURFACE-0.300
- NOTCH_SIGNALING-0.290
- KRAS_SIGNALING_UP-0.270
- IL2_STAT5_SIGNALING-0.250
- INTERFERON_GAMMA_RESPONSE-0.250
- IL6_JAK_STAT3_SIGNALING-0.230
- APICAL_JUNCTION-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E2-A15J-01A-11R-A12P-07 | — | B | 0.836 |
| 2 | MDT-AP-2032 | Med | Medulloblastoma | 0.817 |
| 3 | SRR6013506 | — | cohortA2 | 0.811 |
| 4 | s0112303 | — | — | 0.810 |
| 5 | SRR10900578 | — | — | 0.800 |
| 6 | MNG999 | — | — | 0.789 |
| 7 | MNG843 | — | — | 0.779 |
| 8 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.779 |
| 9 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.766 |
| 10 | SRR10900552 | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.120 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.040 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.040 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.030 | Remibrutinib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.010 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.010 | Inavolisib | — uncovered |